Dr. William Williams reports

BRIACELL THERAPEUTICS ANNOUNCES CLOSING OF $5.5 MILLION PUBLIC OFFERING

Briacell Therapeutics Corp. today closed its previously announced underwritten public offering of 7.4 million common shares and warrants to purchase 7.4 million common shares at a combined public offering price of 75 cents per share and associated warrant. The warrants have an exercise price of 93.75 cents per share and are immediately exercisable upon issuance for a period of five years following the date of issuance. Total gross proceeds from the offering, before deducting the underwriter's discounts and other offering expenses, is $5.55-million.

The company intends to use the net proceeds from the offering for working capital requirements, general corporate purposes and the advancement of business objectives.

ThinkEquity acted as the sole book-running manager for the offering.

The securities were offered and sold pursuant to the company's currently effective shelf registration statement on Form S-3 (file No. 333-276650), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the SEC) on Jan. 22, 2024, and declared effective on Jan. 31, 2024. The offering was made by means of a prospectus supplement and prospectus which have been filed with the SEC and are available on the SEC's website. You should read the prospectus supplement and prospectus for more complete information about the company and the offering. You may obtain these documents free of charge by visiting the SEC website. Alternatively, you may obtain copies by contacting ThinkEquity, 17 State St., 41st floor, New York, N.Y., 10004.

About Briacell Therapeutics Corp.

Briacell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care.

We seek Safe Harbor.